Clinical Trial Update: A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluated intravenous trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer; the study completed and results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Kadcyla (ado-trastuzumab emtansine)

Snippet

Sponsor: Genentech, Inc. | Conditions: Metastatic Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2013-04-02